NAB-7061

NAB-7061 is an investigational **polymyxin-related antimicrobial cationic peptide** developed by **Northern Antibiotics** as a next-generation agent against **Gram-negative bacteria**, particularly multidrug-resistant pathogens. It is structurally related to polymyxin B and colistin, but published preclinical work indicates a **lower affinity for rat kidney brush border membrane** than polymyxin B, suggesting the program was designed to reduce nephrotoxicity risk. Mechanistically, NAB-7061 acts as a **membrane-active antibacterial peptide** in the polymyxin class, interacting with the **outer membrane of Gram-negative bacteria** and increasing membrane permeability; reported studies also describe it as a **sensitizer** that can potentiate the activity of otherwise poorly active antibiotics such as rifampicin and clarithromycin against enteric Gram-negative organisms. Available public information appears limited to preclinical pharmacology and pharmacokinetic studies, with no clear evidence of marketed status.

Other names

NAB 7061 peptideNAB7061 peptideNAB-7061 peptide